BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu M, Tomlinson B. Pharmacokinetic evaluation of lanreotide. Expert Opinion on Drug Metabolism & Toxicology 2010;6:1301-12. [DOI: 10.1517/17425255.2010.513700] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Wauters L, Arts J, Caenepeel P, Holvoet L, Tack J, Bisschops R, Vanuytsel T. Efficacy and safety of lanreotide in postoperative dumping syndrome: A Phase II randomised and placebo-controlled study. United European Gastroenterol J 2019;7:1064-72. [PMID: 31662863 DOI: 10.1177/2050640619862166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gariani K, Meyer P, Philippe J. Implications of Somatostatin Analogues in the Treatment of Acromegaly. Eur Endocrinol 2013;9:132-5. [PMID: 29922369 DOI: 10.17925/EE.2013.09.02.132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 An Z, Lei T, Duan L, Hu P, Gou Z, Zhang L, Durand-Gasselin L, Wang N, Wang Y, Gu F; LANTERN study investigators. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN). BMC Endocr Disord 2020;20:57. [PMID: 32366244 DOI: 10.1186/s12902-020-0524-7] [Reference Citation Analysis]
4 Pavel M, Borson-chazot F, Cailleux A, Hörsch D, Lahner H, Pivonello R, Tauchmanova L, Darstein C, Olsson H, Tiberg F, Ferone D. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. Cancer Chemother Pharmacol 2019;83:375-85. [DOI: 10.1007/s00280-018-3734-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Song YH, Yoon J, Lee SH. The role of neuropeptide somatostatin in the brain and its application in treating neurological disorders. Exp Mol Med 2021;53:328-38. [PMID: 33742131 DOI: 10.1038/s12276-021-00580-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Fattah S, Brayden DJ. Progress in the formulation and delivery of somatostatin analogs for acromegaly. Therapeutic Delivery 2017;8:867-78. [DOI: 10.4155/tde-2017-0064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Fougner SL, Bollerslev J, Svartberg J, Øksnes M, Cooper J, Carlsen SM. Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. Eur J Endocrinol 2014;171:229-35. [PMID: 24866574 DOI: 10.1530/EJE-14-0249] [Cited by in Crossref: 39] [Cited by in F6Publishing: 14] [Article Influence: 4.9] [Reference Citation Analysis]
8 Fleseriu M, Hoffman AR, Katznelson L; AACE Neuroendocrine and Pituitary Scientific Committee. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: MANAGEMENT OF ACROMEGALY PATIENTS: WHAT IS THE ROLE OF PRE-OPERATIVE MEDICAL THERAPY? Endocr Pract 2015;21:668-73. [PMID: 26135961 DOI: 10.4158/EP14575.DSCR] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]